Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza

Influenza and other Respiratory Viruses

Volumn 3, Issue 4, 2009, Pages 177-182

  Ng, Wy Ching ^a   Gilbertson, Brad ^a   Lim, Bock ^a   Zeng, Weiguang ^a   Jackson, David C ^a   Brown, Lorena E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CD8+ T cells; Heterosubtypic immunity; Lipopeptide; Vaccine; Virulent influenza virus

Indexed keywords

GLUTAMINYLALANYLLEUCYLASPARAGINYLASPARAGINYLARGINYLPHENYLALANYLGLUTAMINYLISOLEUCYLLYSYLGLYCYLVALYLGLUTAMYLLEUCYLLYSYLSERINE; INFLUENZA VACCINE; LIPOPEPTIDE; THREONYLTYROSYLGLUTAMINYLARGINYLTHREONYLARGINYLALANYLLEUCYLVALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; LUNG; MEMORY CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS VIRULENCE; WEIGHT REDUCTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BODY WEIGHT; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LIPOPEPTIDES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS;

EID: 67649088294     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2009.00087.x     Document Type: Article

References (33)

1. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines -yesterday, today, and tomorrow. Lancet Infect Dis 2002; 2:425-431.
2. Brown LE, Jackson DC. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv 2005; 2:383-393.
3. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997; 185:1951-1958.
4. Jackson DC, Lau YF, Le T et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101:15440-15445.
5. Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 2006; 18:1801-1813.
6. Schjetne KW, Thompson KM, Nilsen N et al. Cutting Edge: Link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an efficient vaccine target. J Immunol 2003; 171:32-36.
7. Deliyannis G, Jackson DC, Ede NJ et al. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 2002; 76:4212-4221.
8. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC. Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 2002; 76:12388-12393.
9. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300:337-339.
10. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300:339-342.
11. Deliyannis G, Kedzierska K, Lau YF et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006; 36:770-778.
12. Maher JA, DeStefano J. The ferret: An animal model to study influenza virus. Lab Anim (NY) 2004; 33:50-53.
13. Ibricevic A, Pekosz A, Walter MJ et al. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J Virol 2006; 80:7469-7480.
14. Tannock GA, Paul JA, Barry RD. Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 1984; 43:457-462.
15. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002; 169:4905-4912.
16. Jackson DC, Drummer HE, Brown LE. Conserved determinants for CD4+ T cells within the light chain of the H3 hemagglutinin molecule of influenza virus. Virol 1994; 198:613-623.
17. Bodmer HC, Pemberton RM, Rothbard JB, Askonas BA. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 1988; 52:253-258.
18. Christensen JP, Doherty PC, Branum KC, Riberdy JM. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol 2000; 74:11690-11696.
19. Liang S, Mozdzanowska K, Palladino G, Gerhard W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 1994; 152:1653-1661.
20. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009; 9:153-161.
21. Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 2007; 179:2187-2194.
22. Assarsson E, Bui HH, Sidney J et al. Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 2008; 82:12241-12251.
23. Lee LY, Ha do LA, Simmons C et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118:3478-3490.
24. Sette A, Sidney J. HLA supertypes and supermotifs: A functional perspective on HLA polymorphism. Curr Opin Immunol 1998; 10:478-482.
25. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1.
26. Voeten JT, Bestebroer TM, Nieuwkoop NJ, Fouchier RA, Osterhaus AD, Rimmelzwaan GF. Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes. J Virol 2000; 74:6800-6807.
27. McMichael AJ, Gotch FM, Dongworth DW, Clark A, Potter CW. Declining T-cell immunity to influenza, 1977-82. Lancet 1983; 2:762-764.
28. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000; 61: 94-99.
29. Skowronski DM, Masaro C, Kwindt TL et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: Results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842-2851.
30. Fazekas de St G, Webster RG. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 1966; 124:331-345.
31. Yarchoan R, Nelson DL. Specificity of in vitro anti-influenza virus antibody production by human lymphocytes: Analysis of original antigenic sin by limiting dilution cultures. J Immunol 1984; 132:928-935.
32. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983; 309:13-17.
33. Kieny MP, Costa A, Hombach J et al. A global pandemic influenza vaccine action plan. Vaccine 2006; 24:6367-6370.